Jun 16, 2025, 07:52 | Science

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study

Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, Japan, shared a post on…

Jun 5, 2025, 15:07 | Insight

Praveen Kumar Marimuthu: Best of ASCO 2025 - LMIC version

Praveen Kumar Marimuthu, Assistant Professor of Medical Oncology at Christian Medical College and Hospital, shared…

Jun 4, 2025, 03:51 | Blog

Arndt Vogel: 10-year follow up for Pembrolizumab in MSI-H/dMMR Advanced Solid Tumors

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology…

Jun 3, 2025, 18:18 | Insight

Elizabeth McKenna: Study on Vascular Normalization and Enhanced Immunotherapy

Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X about a paper…

Jun 2, 2025, 14:25 | Blog

Gilberto Lopes: Combining ctDNA and ctRNA Liquid Biopsy for Treatment Personalization

Gilberto Lopes, Medical Director for International Programs and Associate Director at the Sylvester Comprehensive Cancer…

May 30, 2025, 14:11 | Insight

HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors

Preliminary results show that DB-1310 is both well-tolerated and effective in patients with heavily pretreated…

May 27, 2025, 13:02 | Blog

Dr E. Shyam P. Reddy on CAR-T and Personalized Gene Therapies

E. Shyam P. Reddy, Professor and Director of the Cancer Biology Program at Morehouse School of…

May 16, 2025, 16:03 | Insight

START Doses 1st US Patient in Moderna's Pan-Tumor Antigen Therapy Study in Solid Tumors

START Doses First U.S. Patient in Moderna’s Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor…

May 1, 2025, 12:14 | Science

Yan Leyfman: A2B694 CAR T Cell Therapy in Solid Tumors

Yan Leyfman, Co-founder and executive director of MedNews Week, shared a post on LinkedIn: "New…

Apr 17, 2025, 16:01 | Blog

Hung Trinh: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients

Hung Trinh, Senior Director of Business Development at OBiO Tech, shared an article by Martin…

Apr 10, 2025, 12:20 | Oncolibrary

New Paper Alert:ctDNA Clearance Predicts pCR in Solid Tumors Treated with Neoadjuvant Immunotherapy

ctDNA (Circulating tumor DNA) has emerged as a transformative biomarker in oncology, offering a minimally…

Apr 1, 2025, 11:50 | Blog

ECOG-ACRIN is now enrolling ComboMATCH-E5 Treatment Trial for patients with advanced Solid Tumors

ECOG-ACRIN Cancer Research Group shared a post on X: "ComboMATCH Treatment Trial E5, led by…

Mar 25, 2025, 12:21 | Insight

Great Debates in Solid Tumors 2025 - Insights from Estela Rodriguez

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of…

Mar 17, 2025, 12:29 | Blog

Jason Luke: Amazing Society for Immunotherapy of Cancer Spring Scientific on cell therapy in solid tumors

Jason Luke, Associate Director for Clinical Research at Hillman Cancer Center, shared a post on…

Mar 5, 2025, 16:21 | Science

Eric Singhi: Phase 1a study of zongertinib in metastatic solid tumors with HER2 alterations

Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas…

Feb 27, 2025, 17:01 | Blog

Chris Boshoff: Pfizer has entered into a clinical trial collaboration with Summit Therapeutics

Chris Boshoff, Chief Oncology Officer and President of Research and Development at Pfizer, shared a…

Feb 9, 2025, 15:33 | Science

Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors

Michael Duruisseaux, Physician-Scientist in the Onco-Pharmacology team at the Lyon Cancer Research Center, shared an…

Jan 20, 2025, 13:56 | Opinion

Amol Akhade: Do oncologists from LMICs and HICs treat and read about only certain solid tumors or all of them?

Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…

Jan 8, 2025, 08:50 | Blog

Survey on the Use of International Guidelines in the Treatment of Solid Tumors

We warmly invite you to participate in a survey exploring the significance and use of…

Dec 28, 2024, 18:11 | Blog

Hesham A. Abdullah: 2024 has been a momentous year for GSK Oncology

Hesham A. Abdullah, Senior Vice President of Global Head Oncology, Research and Development at GSK…

Dec 28, 2024, 18:09 | Drugs

Rami Manochakian: FDA approved subcutaneous Nivolumab for Solid Tumors

Rami Manochakian, Thoracic medical oncologist at Mayo Clinic, shared a post on X: "U.S FDA…

Dec 27, 2024, 08:29 | Blog

Ruben Mesa: Extremely fortunate to have Marissa Howard-Mcnatt for Breast Cancer at Atrium Health Levine Cancer Institute

Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute, reshared a post…

Dec 19, 2024, 21:11 | Science

Liquid Biopsy Response Evaluation Criteria in Solid Tumor - International Society of Liquid Biopsy

International Society of Liquid Biopsy shared a recent article by Mohamed Alaa Gouda on X:…

Dec 16, 2024, 13:01 | Blog

The 2024-2027 AIEOP Board of Directors: Michela Casanova

AIEOP: Italian Association of Pediatric Hematology and Oncology shared a post on LinkedIn: "Meet The…

Dec 11, 2024, 14:53 | Insight

Five articles suggested by Yan Leyfman

Yan Leyfman MD is the Co-founder and executive director of MedNews Week. He is also the…

Dec 5, 2024, 11:28 | Insight

Exercising and immuno-oncology treatment for patients with solid tumors

Enrique Grande shared a post on X: "Exercise + immunotherapy? This study shows the feasibility…

Nov 30, 2024, 16:01 | Blog

IL-15 to enhance the effectiveness of GPC3-targeting CAR T cells in solid tumors

Yan Leyfman shared on LinkedIn: "Study from Baylor College of Medicine showed that IL-15 enhances the…

Nov 14, 2024, 16:22 | Insight

Guru P. Sonpavde: Largest analysis of association of irAEs efficacy

Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X: “Immunotherapy…

Nov 11, 2024, 23:44 | Insight

Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors

Niklas Klümper, Senior Consultant for Urology and GU Oncology at University Hospital Bonn, shared a…

Nov 9, 2024, 12:04 | Insight

Celebrating 40 Years of TCR Discovery: A Gathering of Giants in T Cell Immunology

This year marks the 40th anniversary of the discovery of the T cell receptor (TCR),…

Nov 7, 2024, 13:07 | Blog

Francisco Conesa Buendía: Advancing CAR-T Cell Therapy for Solid Tumors

Francisco Conesa Buendía, Assistant of Cell and Gene Therapies Manufacturing at Memorial Sloan Kettering Cancer…

Oct 26, 2024, 10:49 | Blog

AMG193 shows antitumor activity in MTAP-deleted solid tumors

Ben Westphalen, Chair of the Translational Research and Precision Medicine Working Group, shared a recent…

Oct 8, 2024, 13:41 | Blog

SOLID Therapeutics receives Innobooster grant

SOLID Therapeutics shared a post on LinkedIn: ''Funding News! We’re thrilled to announce that Innovation…

Sep 15, 2024, 15:20 | Insight

Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar…

Sep 14, 2024, 14:02 | Blog

Amol Akhade: Advanced cell therapy for solid tumors - Where do we stand?

Amol Akhade posted the following on LinkedIn: “I don’t know who should know this more…

Aug 28, 2024, 14:58 | Blog

iOmx Therapeutics Initiates Phase Ib with OMX‑0407

iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company translating unexplored immune evasion biology into a…

Aug 23, 2024, 06:22 | Blog

Highlights from the 2024 Seattle Cellular Therapy Summit

The 2024 Seattle Cellular Therapy Summit will feature leading experts who will provide a detailed…

Aug 22, 2024, 04:53 | Insight

Angelo Dipasquale: 20 years of Circulating Tumor Cells and Liquid Biopsy in Solid Tumors

Angelo Dipasquale shared on LinkedIn: “20 years of Circulating Tumor Cells and Liquid Biopsy in…

Aug 9, 2024, 05:53 | Blog

Nivolumab with and without ipilimumab in solid tumors of high mutational burden - Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer shared a post on X, about recent paper published in…

Aug 5, 2024, 17:22 | Blog

The 2025 SITC Spring Scientific on Cell Therapy for Solid Tumors

Society for Immunotherapy of Cancer shared a post on X: "Announcing the 2025 SITC Spring…

Jul 24, 2024, 14:57 | Blog

Peter Lebowitz: Third Arc Bio is launching with the closing of $165 million Series A financing

Peter Lebowitz, CEO of Third Arc Bio, shared a post on Linkedin: "Today marks a…

Jul 22, 2024, 23:08 | Blog

Hung Trinh: TOP CAR with TMIGD2 as a safe and effective domain treating human solid tumors

Hung Trinh, Director of Process Development and MFG Science and Technology at Vyriad, posted on LinkedIn:…

Jul 20, 2024, 11:44 | Blog

Sumanta K. Pal: A terrific review on ADCs in solid tumors led by Salvador Jaime-Casas

Sumanta K. Pal shared on X: "A terrific review on ADCs in solid tumors led…

Jul 17, 2024, 21:50 | Blog

Kimryn Rathmell: New cellular immunotherapy may be effective in treating metastatic solid tumors

Kimryn Rathmell shared a post on X: ''Hot off the press from Steven Rosenberg and…

Jul 17, 2024, 21:49 | Blog

Daily oral zelenirstat for advanced solid tumors and R/R B-cell lymphomas

Naveen Pemmaraju shared on X: ''A first-in-human phase I trial of daily oral zelenirstat, a…

Jul 17, 2024, 02:26 | Insight

Patrick Hwu: When patients with solid tumors don’t respond to immunotherapy

Patrick Hwu shared a post on X about a recent paper by Maria Parkhurst et…

Jul 10, 2024, 07:24 | Drugs

How well sotorasib with or without panitumumab can treat patients with advanced Solid Tumors - ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group shared on X: "ComboMATCH/EAY191-E5 tests how well sotorasib with or without…

Jul 10, 2024, 06:36 | Insight

Paolo Tarantino: Intersecting data with the MAT2A inhibitor IDE397 in MTAPdel lung and urothelial cancer

Paolo Tarantino shared a post by Bio Stocks on X, adding: . "Intersecting data with…

Jul 7, 2024, 17:41 | Blog

Miguel Bronchud: The importance of well-designed Randomized Controlled Trials

Miguel Bronchud, Co-Founder of Regenerative Medicine Solutions, shared a post on LinkedIn: “I am not…

Jul 2, 2024, 10:50 | Insight

The path to leptomeningeal metastasis

Jean-Charles Soria shared a post on LinkedIn: . "Leptomeningeal metastasis occurs in 5-10% of patients…

Jun 27, 2024, 12:32 | Insight

Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525

Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, shared on LinkedIn: “We are…

Jun 18, 2024, 02:59 | Blog

Estela Rodriguez: Another tumor - agnostic approval

Estela Rodriguez shared a post on X: "Another tumor-agnostic approval. FDA Oncology grants accelerated approval…

Jun 16, 2024, 13:37 | Drugs

Stephen Liu: FDA approves repotrectinib for NTRK fusion positive solid tumors

Stephen Liu recently shared a post on X: “FDA approves repotrectinib for NTRK fusion positive…

Jun 14, 2024, 15:26 | Blog

Best practices in treating patients with solid-tumor and malignant hematology - Roswell Park

Roswell Park made the following post on X: Join us for the inaugural Upstate NY…

Jun 13, 2024, 07:54 | Blog

Connect to the ESMO Virtual Plenary to stay up to date with the latest in immunotherapy

ESMO shared on LinkedIn: "What are the early safety and activity profiles of a first-in-class PD-1/IL-2…

Jun 13, 2024, 05:48 | Blog

Rabab Hunaid Abbas: An exclusive keynote event with Dr. Thomas Marron

Rabab Hunaid Abbas, Member at Georgian International Medical Student Society, shared a post on LinkedIn: "Upcoming…

Jun 8, 2024, 11:07 | Insight

Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors

MD Anderson researchers share preliminary clinical data of an antibody-drug conjugate for metastatic colorectal cancer…

Jun 7, 2024, 16:55 | Career

Sunil Verma: Day 1 in AstraZeneca as SVP, Global Head, Oncology Franchise

Sunil Verma shared on X: . "Day 1 in the…

Jun 5, 2024, 10:12 | Societies

Samin Saeed: My first time at ASCO

Samin Saeed, Chief Medical Officer at Random42 Scientific Communication, shared a post on LinkedIn: "At…

Jun 1, 2024, 12:11 | Societies

Carlos Torrado: Excited to present our poster at ASCO24

Carlos Torrado, Clinical Fellow at MD Anderson Cancer Center, recently shared a post by NCI…

May 22, 2024, 08:39 | Blog

Tanja Obradovic: ASCO just published guidelines for germline genetic testing panels

Tanja Obradovic shared on LinkedIn: "Great service to public and oncology community as ASCO just published…

May 21, 2024, 04:43 | Blog

Clinical and Translational Oncology PhD Programme participant Alaa Embaby's theses

The Clinical and Translational Oncology PhD Programme shared on LinkedIn: "On Tuesday May 21st, our…

May 16, 2024, 08:20 | Blog

Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise

Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise Cash runway…

May 14, 2024, 15:00 | Drugs

Ravi Karra discusses overcoming challenges in early phase drug development for solid tumors - Advanced Clinical

Advanced Clinical shared on LinkedIn: . "Innovative trial designs and advanced imaging modalities could address…

May 9, 2024, 00:21 | Blog

Enes Erul: Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors

Enes Erul, Oncology Fellow at Ankara Üniversitesi, shared on X: “Trastuzumab deruxtecan shows promise in HER2-mutant…

Apr 26, 2024, 20:41 | Insight

Piotr Wysocki: CAR-T therapy seems to be associated with second primary malignant neoplasms

Piotr Wysocki recently shared on LinkedIn: "In a research letter published online in JAMA Oncology,…

Apr 26, 2024, 17:55 | Insight

Piotr Wysocki: NECTIN4 amplification is a predictive factor for enfortumab vedotin efficacy

Piotr Wysocki recently shared on LinkedIn: "Kluemper et al. published results of a study evaluating NECTIN4…

Apr 26, 2024, 07:37 | Blog

Meet the Author Amin H. Nassar by Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer shared on X/Twitter: "Meet the Author: Amin H. Nassar, a medical…

Apr 21, 2024, 23:34 | Blog

Svetlana Nikic: Comprehensive and structured list of FDA-approved CDx NGS assays. Super easy to be found at FDA's website

Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn: "With an overwhelming amount…

Apr 21, 2024, 11:35 | Insight

Samuel Kareff: Our pan-tumor analysis on the not-so-elusive HRAS mutation in solid tumors

Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, shared…

Apr 20, 2024, 08:16 | Blog

Tanja Obradovic: One exciting novel approach is just about to enter clinical development

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post on LinkedIn: "Cell…

Apr 20, 2024, 07:47 | Drugs

Paper summary by Marco Donia

Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared a post on…

Apr 19, 2024, 05:17 | Insight

Dina Schneider: Excited about our recent publication on Armored TGFBRIIdn ROR1-targeting CAR T cells for solid tumors

Dina Schneider, Director of Immuno Oncology and Cell Therapy at Lentigen Technology, shared on LinkedIn:…

Apr 18, 2024, 13:05 | Blog

MD Anderson and CureVac have launched a strategic collaboration to develop off-the-shelf mRNA-based cancer vaccines

MD Anderson Cancer Center shared a post on LinkedIn: "MD Anderson and CureVac have launched a…

Apr 17, 2024, 00:52 | Insight

UHN Research - Can a blood sample be used to predict patient outcomes to cancer immunotherapy drug pembrolizumab?

UHN Research shared on their LinkedIn: "Can a blood sample be used to predict patient…

Apr 16, 2024, 13:31 | Blog

Sarabjot Pabla: What an incredible opportunity it was to be part of AACR2024

Sarabjot Pabla, Head of Clinical and Research Bioinformatics at OmniSeq, shared on their LinkedIn: ''What…

Apr 12, 2024, 09:45 | Blog

Estela Rodriguez: Proud to work with LUNGevity Foundation and team to develop a discussion guide for biomarker testing for patients with solid tumors in plain language

Estela Rodriguez shared on X/Twitter: "Proud to work with LUNGevity Foundation and team to develop a discussion…

Apr 8, 2024, 16:01 | Drugs

Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical…

Apr 8, 2024, 15:41 | Drugs

Tom Powles: This seems an ambitious accelerated approval in UC

Tom Powles, Director of Barts Cancer Center, recently shared on X: "TDXD received FDA accelerated…

Apr 8, 2024, 15:17 | Blog

Petros Grivas: Can’t wait to join Paolo Tarantino and Helena Yu to review ADCs across solid tumors

Petros Grivas, Associate Professor at the University of Washington, recently shared a post by Paolo…

Apr 8, 2024, 13:02 | Blog

Eric K. Singhi: Proud to work with LUNGevity Foundation and team to develop a discussion guide for biomarker testing for patients with solid tumors

Eric K. Singhi, Thoracic Medical Oncologist and Assistant Professor at the MD Anderson Cancer Center, recently…

Apr 7, 2024, 07:20 | Insight

Wafik El-Deiry: Dr. Alice Shaw speaks about directions in ADC’s in cancer therapy at AACR 2024

Wafik El-Deiry, Director of the Legorreta Cancer Center at Brown University, recently posted on LinkedIn:…

Mar 29, 2024, 05:47 | Blog

Nitin Jain: Fantastic talk by Dr Hind Rafei on current status of NK cell therapy

Katy Rezvani Chief of Section of Cellular Therapy, Department of Stem Cell Transplantation and Cellular…

Feb 23, 2024, 17:44 | Drugs

Allison Betof Warner: The TIL team at Stanford Cancer Institute did our first surgical tumor harvest for AMTAGVI (lifileucel) this morning!

Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford…

Feb 23, 2024, 10:51 | Blog

Amer Zeidan: Just an unbelievable cascade of news for magrolimab

Amer Zeidan shared on X: "Just an unbelievable cascade of news for magrolimab … Gilead…

Feb 19, 2024, 18:12 | Career

Giles Robinson: Congratulations Sara Federico on being named the director of the Solid Tumor Division at the St. Jude Children’s Research Hospital

Giles Robinson, Neuro-Oncology Division Director at the St. Jude Children’s Research Hospital, shared on X/Twitter:…

Feb 19, 2024, 04:12 | Dialogues

OncoDaily Walk and Talk with Maite Gorostegui, Hosted by Tatev Margaryan

Welcome back to Walk & Talk on OncoDaily! Our guest for today is Dr. Maite…

Jan 22, 2024, 09:50 | Blog

Wei Zhang: Glad to see IGFBP2 as the top plasma marker for early cancer detection of 18 types of solid tumors

Wei Zhang, Director of Cancer Genomics and Precision Oncology, shared on LinkedIn: ''Early Cancer Detection…

Jan 7, 2024, 09:31 | Blog

Kunal Desai: I’ll be joining AbbVie as Medical Director in their late-stage solid tumors clinical development team

Kunal Desai, Oncology Fellow at University of Chicago, shared a post on X/Twitter: "Now is a…

Dec 25, 2023, 16:45 | Insight

Vivek Subbiah: Pleased to share the work of our amazing RET precision medicine team as we review

Vivek Subbiah shared on LinkedIn: "Hot off the press! Pleased to share the work of…

Dec 23, 2023, 04:00 | Insight

Vivek Subbiah: Such a delight to share our non-human primate publication as a pre-cursor to our First-in-human phase 1 trial

Vivek Subbiah shared on X/Twitter: ''Such a delight to share our non-human primate publication on First-in-cynomolgus…

Dec 8, 2023, 17:50 | Drugs

Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society

The Antibody Society shared on their LinkedIn page: "In an unusual (to us anyway) move,…

Oct 23, 2023, 13:31 | Drugs

At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma

Agenus shared on their LinkedIn page: "At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational…